

ASX Market Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

8 April 2024

Notice Under Section 708A(5)(e) of the Corporations Act

This notice (**Notice**) is given by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (ASX: CU6) (**Company** or **Clarity**) pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

Clarity has today issued 39,468,752 new fully paid ordinary shares (each a **New Share** and together the **New Shares**) at an issue price of \$2.55 per New Share, representing all of the shares to be issued pursuant to the placement to institutional investors as part of the equity raising announced by the Company on 26 March 2024, and pursuant to the Company's available capacity under ASX Listing Rule 7.1.

The Company advises that:

- a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- b) this Notice is being given under and in accordance with section 708A(5)(e) of the Corporations Act;
- c) as at the date of this Notice, the Company has complied with:
 - i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii) sections 674 and 674A of the Corporations Act; and
- d) as at the date of this Notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be set out in this Notice.

An application for quotation of securities (Appendix 2A) with respect to the News Shares issued was lodged with ASX on Friday, 5 April 2024.

Robert Vickery
Company Secretary

This announcement has been authorised for release by Dr Alan Taylor, Executive Chairman.

For more information, please contact:

Dr Alan Taylor
Executive Chairman
ataylor@claritypharm.com

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com